Repligen | RGEN - Ordinary Share Capital


Repligen reported $56.69M in Ordinary Share Capital for its fiscal quarter ending in September of 2026.





Ordinary Share Capital Change Date
Agilent USD 281.97M 252K Jun/2026
Align Technology USD 71.62M 1000 Jun/2026
Bio Techne USD 156.45M 703K Mar/2026
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Bruker USD 152.35M 130K Jun/2026
Charles River Laboratories USD 47.73M 439K Jun/2026
Danaher USD 703.4M 500K Sep/2026
Dentsply International USD 199.2M 1.1M Jun/2026
General Electric Aerospace USD 1.03B 4.21M Sep/2026
Henry Schein USD 111.92M 2.51M Jun/2026
Illumina USD 151.3M 607K Jun/2026
IQVIA Holdings USD 164.6M 2.3M Jun/2026
Mettler Toledo International USD 20.21M 40.9K Jun/2026
Myriad Genetics USD 93.5M 400K Dec/2025
OraSure Technologies USD 70.39M 1.87M Dec/2025
Pacific Biosciences Of California USD 301.96M 103K Dec/2025
Pfizer USD 5.7B 0 Jun/2026
Repligen USD 56.69M 266K Sep/2026
Revvity USD 111.63M 174K Jun/2026
Standard Biotools USD 390.14M 3.76M Mar/2026
Thermo Fisher Scientific USD 369.75M 1.88M Sep/2026
Waters USD 98.19M 20K Jun/2026
West Pharmaceutical Services USD 70.4M 500K Jun/2026